'Brca mutation' diaporamas de présentation

Cancer Screening and Immunizations in Adults

1.3k views • 98 slides

Recent advances in MRI Breast and Future

Recent advances in MRI Breast and Future. Dr.Rattehalli R Ramachandra Consultant Radiologist University Hospitals Coventry & Warwick NHS trust. Introduction. Timeline of Breast diagnosis Role of MRI Breast Recent advances Other modalities Conclusion. Breast cancer UK.

1.18k views • 93 slides

Hereditary ovarian / breast cancers (HOC /HBOC )

767 views • 44 slides

Best of ASCO in Gyn Oncology

Best of ASCO in Gyn Oncology. Adnan R Munkarah. Biologics in Recurrent Ovarian Ca. Cediranib - highly selective and potent oral TK inhibitor of VEGFR1, VEGFR2, VEGFR3 and c-Kit( Matulanis #5501, Hirte#5521 ) Sunitinib - multitargeted RTK inhibitor ( Biagi #5522 )

569 views • 39 slides

???? Genetic Screening

???? Genetic Screening. ???? ????? ? ? ?. Breast cancer. Breast cancer susceptibility genes. * Breast cancer penetrance in mutation carriers. Problems in genetic screening of breast cancer. No unifying molecular alteration in sporadic breast cancer (genetically heterogeneous)

517 views • 29 slides

Simple.

THE SECTION ON Evidence Based Health Care OF THE NEW YORK ACADEMY OF MEDICINE. 2014 TEACH Workshop. Simple. Scientifically Informed Medical Practice and Learning. Suzana Alves da Silva, MD, MSc, PhD, FNYAM. Clinical Problems. P. I. C. O. What we know?.

358 views • 20 slides

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer. Andrea Wahner Hendrickson M.D. March 8, 2018. MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer. How do PARP inhibitors work? Why do they work better for some ovarian cancer over others?

842 views • 19 slides

Legal issues related to genetic diagnostics Genomic Information Non-discrimination Act (GINA) what is covered, what not

Legal issues related to genetic diagnostics Genomic Information Non-discrimination Act (GINA) what is covered, what not risk alleles for Alzheimers disease long-term care insurance adverse selection Patents - theoretical quid pro quo weighing benefits vs harms

297 views • 15 slides

The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers

The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers. Background. Inhibiting polyADP polymerase is key in the treatment of cancers that have DNA-repair defects. Methods.

152 views • 5 slides

Table 3 Ipsilateral and contralateral risk after treatment based on studies of BRCA genotype and age at diagnosis. Trainer, A. H. et al. (2010) The role of BRCA mutation testing in determining breast cancer therapy Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.175.

201 views • 1 slides